-
Mashup Score: 0Second-Generation Antiandrogens Linked to Falls, Cognitive Toxicity in Prostate Cancer Patients - 9 month(s) ago
Prostate cancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Preventing and Treating Malnutrition in Cancer Patients - 9 month(s) ago
Malnutrition may affect 30% to 85% of cancer patients, and it may account for 10% to 20% of deaths in these patients.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Malnutrition is a major concern for cancer patients, especially those undergoing intense treatments, says our clinical dietitian Katie Roberts. Get her insights on how to help patients avoid malnutrition: https://t.co/XDd3w8Jh12 @CancerTherAdvsr #EndCancer
-
-
Mashup Score: 0How to Treat Gastrointestinal Cancers During the Chemotherapy Shortage - 10 month(s) ago
ASCO has released recommendations outlining how to treat patients with gastrointestinal cancer while chemotherapy drugs are in short supply.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The American Society of Clinical Oncology has released recommendations outlining how to treat patients with #gastrointestinalcancer while certain chemotherapy drugs are in short supply. https://t.co/K1ni3pBRc1 #GastricCancer
-
-
Mashup Score: 0
Patients with HR+, HER2- metastatic breast cancer whose disease progressed on endocrine therapy (ET) and a CDK4/6 inhibitor have better progression-free survival if they switch ET and receive ribociclib than if they switch ET alone, a phase 2 study suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with HR-positive, HER2-negative metastatic #breastcancer whose disease progressed on endocrine therapy and a CDK4/6 inhibitor have better PFS if they switch ET and receive ribociclib than if they switch ET alone. Published in @JCO_ASCO. https://t.co/xRfRqTKok0 #BCSM
-
-
Mashup Score: 0
A majority of lymphoma patients who relapse during pregnancy can have a live birth, even if treatment is initiated antenatally, a study suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A majority of patients with #lymphoma who relapse during pregnancy can have a live birth, even if treatment is initiated antenatally. Published in @BloodAdvances. https://t.co/g1fDvHnrlv #HemOnc
-
-
Mashup Score: 0
An all-oral triplet regimen is safe and effective in patients with newly diagnosed acute promyelocytic leukemia, a phase 2 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An all-oral triplet regimen appears safe and effective in patients with newly diagnosed #acutePromyelocyticLeukemia. Presented at the @EHA_Hematology #EHA2023. https://t.co/O4u5VTZTXm #APL #leusm
-
-
Mashup Score: 0Opinion: Surgeon Collaboration Is Key to Mitigating Post-Mastectomy Chest Numbness - 10 month(s) ago
Breast surgeons and plastic reconstructive surgeons should work together to care for nerves in the breasts during breast cancer surgery.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An all-too-common — but not often talked about — side effect of #mastectomy is chest numbness. In one study, 65% of patients consistently reported numbness in the 12 months after #breastcancer surgery. Reported in @PainReportsOPEN. https://t.co/0OtcyQAs09 #BCSM
-
-
Mashup Score: 1Anticoagulants Do Not Reduce Risk of Arterial Thrombotic Events in Cancer Patients - 10 month(s) ago
Anticoagulants do not reduce the risk of arterial thrombotic events in ambulatory cancer patients on systemic therapy, a review suggests.
Source: Cancer Therapy AdvisorCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A #JACCCardioOnc study found that anticoagulants do not decrease the risk of ATEs for ambulatory cancer patients on systemic therapy. Read more in @CancerTherAdvsr: https://t.co/dKyqpfTKjz #cvCoag
-
-
Mashup Score: 1
Zorifertinib improves PFS when compared to gefitinib or erlotinib as first-line treatment for EGFR-mutant NSCLC with CNS metastases, a phase 3 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zorifertinib improves PFS when compared to gefitinib or erlotinib as first-line treatment for EGFR-mutant non-small cell #lungcancer with central nervous system metastases. Presented at @ASCO #ASCO23. https://t.co/wOCxeZpttT #NSCLC
-
-
Mashup Score: 0Mirvetuximab Soravtansine Deemed New Standard Care in FRα+ Platinum-Resistant Ovarian Cancer - 10 month(s) ago
Mirvetuximab soravtansine is the first novel treatment to demonstrate a benefit in overall survival in platinum-resistant ovarian cancer in a phase 3 trial.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mirvetuximab soravtansine improves outcomes over chemotherapy in patients with platinum-resistant #ovariancancer with high FRα expression. Presented at the @ASCO #ASCO23. https://t.co/mnp55Hoouq #gyncsm
-
#Prostatecancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity. Published in @JAMAOnc. https://t.co/pZ98cIQv0g #PCSM